The Quest for Alzheimer’s Treatment: Controversies and New Theories

Finding a cure for Alzheimer’s disease is becoming increasingly competitive, and recent years have seen significant controversies arise. For instance, a Science magazine report in July 2022 raised questions about a pivotal research paper from 2006 published in Nature. This paper identified beta-amyloid, a subtype of brain protein, as a key cause of Alzheimer’s; however, it may have been based on fabricated data.

Earlier, in June 2021, the US Food and Drug Administration approved aducanumab, an antibody aimed at beta-amyloid. This decision sparked debate, as the supporting research was incomplete and even contradictory. While some physicians argue that aducanumab should never have been approved, others think it deserves a chance. With millions searching for effective treatment, the question arises: why are researchers grappling with finding a solution for such a crucial ailment?

Rethinking Alzheimer’s Research

For years, scientists have fixated on developing treatments that prevent the formation of damaging beta-amyloid clumps. This focus, while important, has perhaps led to an intellectual rut, sidelining other potential explanations. Unfortunately, this dedication hasn’t yet yielded a breakthrough drug or therapy. There’s a growing need for a fresh perspective on Alzheimer’s in brain science.

At the Krembil Brain Institute in Toronto, my lab is formulating a new theory about Alzheimer’s. Based on three decades of research, we now consider Alzheimer’s more as a disorder of the brain’s immune system rather than just a brain disease.

The immune system is vital in every organ, coordinated to help repair injuries and fend off foreign threats. In the brain, when trauma occurs or bacterial infections are present, the immune system activates to assist in repair or defense.

Alzheimer’s as an Autoimmune Disease

In our view, beta-amyloid isn’t just an irregularly produced protein; it’s a naturally occurring molecule integral to the brain’s immune response. However, when brain trauma or bacteria invade, beta-amyloid struggles to differentiate between harmful and healthy cells, leading it to erroneously attack brain cells that it should protect.

This misdirected immune attack results in a chronic decline in brain cell function, ultimately leading to dementia. Thus, we propose that Alzheimer’s may actually be classified as an autoimmune disease.

While treatments typically effective for other autoimmune conditions might not work for Alzheimer’s, we strongly believe that exploring different immune-regulating pathways in the brain could reveal new treatment possibilities.

Emerging Theories of Alzheimer’s

In addition to our autoimmune hypothesis, various other theories are surfacing. For instance, some researchers suggest that Alzheimer’s could stem from issues with mitochondria, the energy providers for brain cells. Others are investigating the potential role of specific brain infections, often linking it to bacteria originating from the mouth. Additionally, some believe that abnormalities in how the brain handles metals like zinc, copper, or iron could contribute to the disease.

It’s encouraging to observe renewed interest in understanding this long-standing ailment. Currently, dementia affects over 50 million individuals globally, with a new diagnosis about every three seconds. Often, those with Alzheimer’s may not even recognize their own family members. This highlights how critical it is to innovate and reassess our understanding of Alzheimer’s and its treatment.

As we look to the future, it’s essential to gain deeper insights into Alzheimer’s, its underlying causes, and how we can better support those affected by this condition, both for their welfare and the overall burden on our healthcare systems.